Galway based cancer treatment company awarded Enterprise Ireland Innovation Partnership Programme grant.

Galway based life science company, ONK Therapeutics has been awarded an Innovation Partnership Programme grant by Enterprise Ireland to fund collaborative research at Trinity College Dublin on optimising the metabolism of Natural Killer (NK) cells for use in potent new cancer therapies.

The research programme is worth €373,295 and is co-funded by ONK and Enterprise Ireland.

ONK Therapeutics was founded in Galway in 2015. It is focused on cutting edge NK cell therapies in cancer treatments and has raised over €10 million in the past 14 months from investors including US based Acorn Bioventures and Irish based life science entrepreneur Seamus Mulligan.

Pictured are (l-r) Dr. David Finlay, Associate Professor in Immunometabolism at Trinity College Dublin, Professor Michael O’Dwyer, Founder and CSO of ONK Therapeutics and Lawrence Lee, Manager Innovation Partnership Programme at Enterprise Ireland